PCML
LGND icon

Pavaki Capital Management LLC’s Ligand Pharmaceuticals LGND Stock Holding History

Pavaki Capital Management LLC’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.51M Hold
11,100
– – 1.22% 17
2026
Q1 		$2.22M Hold
11,100
– – 0.94% 21
2025
Q4 		$2.1M Buy
+11,100
New +$2.13M 0.82% 27

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Pavaki Capital Management LLC's LGND Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Ligand Pharmaceuticals (LGND) position steady in Q2 2026 at 11,100 shares worth $3.51M. The position accounts for 1.22% of the portfolio, ranked #17.

Pavaki Capital Management LLC first reported a position in LGND in Q4 2025 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold LGND as of Q2 2026.

  • Pavaki Capital Management LLC held 11,100 shares of Ligand Pharmaceuticals worth $3.51M as of Q2 2026.
  • Pavaki Capital Management LLC left its Ligand Pharmaceuticals share count unchanged in Q2 2026.
  • Ligand Pharmaceuticals made up 1.22% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #17 holding.
  • Pavaki Capital Management LLC first reported a position in Ligand Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.